首页> 外文期刊>Veterinary Ireland Journal >CURRENT VETERINARY ISSUES IN EUROPE
【24h】

CURRENT VETERINARY ISSUES IN EUROPE

机译:欧洲当前的兽医问题

获取原文
获取原文并翻译 | 示例
           

摘要

"The European Commission will presume the highest ambition for the review of the veterinary medicines legislation... We see strong possibilities to make a good contribution to the reduction of the administrative burden for national competent authorities, veterinarians and manufacturers - in other words a win-win-win situation." Commissioner Daili's opening address to the 2011 IFAH-Europe conference 'Veterinary Medicines Review - The Big Debate' were music to the ears of the organisers. IFAH-Europe isthe representative body of manufacturers of veterinary medicines, vaccines and other animal health products and the purpose of this conference was to kick-start the debate on forthcoming review of the legislation, as well as creating an opportunity forthe industry to present their vision. This was a high-profile conference with representatives of European institutions, farmers, veterinarians, pharmaceutical industry and national authorities all in attendance. There was general agreement that the current legislative regime is in need of an overhaul with a number of significant problems having arisen in recent years. Firstly, the lack of availability of veterinary medicines is of concern to all parties. This is a particular problem in smaller markets and for minor species. Over 70% of authorised medicines are for dogs, cats, pigs or cows. There is also the incongruous situation whereby veterinarians in one Member State have access to a product that is not available to their colleagues across the border, and may even be illegal to use or possess there. Secondly, the processes for authorising veterinary medicines have become very complex, resulting in a high administrative burden for regulators and industry. While there is a centralised procedure, whereby a product can receive an EU-wide marketing authorisation, the majority of authorisations are still carried out by Member State authorities. With 27 national authorities in existence, duplication of labour is a significant issue, both for
机译:“欧洲委员会将以最高雄心勃勃的方式审查兽药立法……我们看到为减轻国家主管部门,兽医和制造商的行政负担做出巨大贡献的巨大可能性,换句话说,就是胜利-双赢局面。”戴利专员在2011年IFAH-欧洲会议“兽药评论-大辩论”上的开幕词在组织者耳中是个音乐。 IFAH-Europe是兽药,疫苗和其他动物保健产品制造商的代表机构,本次会议的目的是启动有关即将进行的立法审查的辩论,并为该行业提供一个表达其愿景的机会。这是一次高调的会议,欧洲机构,农民,兽医,制药业和国家主管部门的代表都参加了会议。大家普遍同意,目前的立法体制需要改革,近年来出现了许多重大问题。首先,缺乏兽药是各方关注的问题。在较小的市场和小型物种中,这是一个特别的问题。超过70%的授权药物是用于狗,猫,猪或牛的。还有一种不协调的情况,即一个会员国的兽医获得其跨境同事无法获得的产品,甚至可能在该国非法使用或拥有。其次,兽药的授权程序变得非常复杂,给监管机构和行业带来了沉重的行政负担。尽管有一个集中的程序,产品可以通过该程序获得欧盟范围内的营销授权,但大多数授权仍由成员国当局执行。现有27个国家主管部门,重复劳动是一个重要问题,

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号